| What causes aplastic anaemia? |
|
Leukemia |
Aplastic Anemia |
| Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia |
|
Blood |
Aplastic Anemia |
| Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care |
|
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
| VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases |
|
Internal and Emergency Medicine |
Myelodysplastic Syndromes (MDS) |
| Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents |
|
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
| PNH and complement gene variants |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study |
|
Journal of Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
